PARIS and TARRYTOWN, N.Y., March 10, 2018 /PRNewswire/ — Sanofi (EURONEXT: SAN) (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. today announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing Praluent® (alirocumab) Injection significantly reduced the risk of major advers…
